Search

Your search keyword '"Ana C. Medeiros"' showing total 3 results
Start Over Author "Ana C. Medeiros" Language english
3 results on '"Ana C. Medeiros"'

1. Immunogenicity decay and case incidence six months post Sinovac-CoronaVac vaccine in autoimmune rheumatic diseases patients

Author

Clovis A. Silva, Ana C. Medeiros-Ribeiro, Leonard V. K. Kupa, Emily F. N. Yuki, Sandra G. Pasoto, Carla G. S. Saad, Solange R. G. Fusco, Rosa M. R. Pereira, Samuel K. Shinjo, Ari S. R. Halpern, Eduardo F. Borba, Fernando H. C. Souza, Lissiane K. N. Guedes, Renata Miossi, Karina R. Bonfiglioli, Diogo S. Domiciano, Andrea Y. Shimabuco, Danieli C. O. Andrade, Luciana P. C. Seguro, Ricardo Fuller, Percival D. Sampaio-Barros, Ana P. L. Assad, Julio C. B. Moraes, Claudia Goldenstein-Schainberg, Henrique A. M. Giardini, Henrique C. Silva, Victor A. O. Martins, Lorena E. B. Villamarin, Renata S. Novellino, Lucas P. Sales, Carlo S. R. Araújo, Matheus S. R. Silva, Dilson M. N. Filho, Marta H. Lopes, Alberto J. S. Duarte, Esper G. Kallas, Nadia E. Aikawa, and Eloisa Bonfa

Subjects
Science
Abstract

Characterising the response to SARS-CoV-2 post vaccination is critical in the appraisement of the induced immune response, performance and protective potential. Here the authors present data from a phase 4 clinical trial in autoimmune rheumatic disease patients 6 months post second dose of Sinovac-CoronaVac inactivated vaccine that show a marked reduction in antibody particularly in males or those under treatment with immune targeting therapies but saw no rise in COVID-19 disease.

Published
2022
Full Text
View/download PDF

2. Infliximab Induces Increase in Triglyceride Levels in Psoriatic Arthritis Patients

Author

Karla R. Castro, Nádia E. Aikawa, Carla Gonçalves Saad, Júlio C. B. Moraes, Ana C. Medeiros, Licia Maria H. Mota, Clovis A. A. Silva, Eloísa Bonfá, and Jozélio F. Carvalho

Subjects
Immunologic diseases. Allergy, RC581-607
Abstract

Objectives. To evaluate lipid profile changes after anti-TNF therapy in patients with psoriatic arthritis (PsA). Methods. Fifteen PsA patients (eight polyarticular, four oligoarticular, two axial, and one mutilating) under infliximab were included. None had dyslipoproteinemia or previous statin use. Total cholesterol (TC) and its fractions, inflammatory markers, and prednisone use were evaluated. Results. The comparisons of lipid levels between baseline and after three months (3M) of anti-TNF therapy showed that there was a significant increase in mean triglycerides (117.8±49.7 versus 140.1±64.1 mg/dL, P=0.028) and VLDL-c (23.6±10.5 versus 28.4±13.7 mg/dL, P=0.019) levels. In contrast, there were no differences in the mean TC (P=0.28), LDL-c (P=0.42), and HDL-c (P=0.26) levels. Analysis of the frequencies of each lipid alteration at baseline and at 3M were alike (P>0.05). Positive correlations were found between VLDL-c and CRP (r=0.647, P=0.009) and between triglycerides and CRP (r=0.604, P=0.017) levels at 3M. ESR reduction was observed after 3M (P=0.04). Mean prednisone dose remained stable at beginning and at 3M (P=0.37). Conclusion. This study demonstrated that anti-TNF may increase TG and VLDL-c levels in PsA patients after three months.

Published
2011
Full Text
View/download PDF

3. Infliximab Induces Increase in Triglyceride Levels in Psoriatic Arthritis Patients

Author

Jozélio Freire de Carvalho, Licia Maria Henrique Mota, Carla G. S. Saad, Nadia E. Aikawa, Ana C. Medeiros, Karla R. Castro, Julio C. B. Moraes, Eloisa Bonfa, and Clovis A. Silva

Subjects
Adult, Male, lcsh:Immunologic diseases. Allergy, medicine.medical_specialty, Article Subject, Immunology, Cholesterol, VLDL, Arthritis, Gastroenterology, chemistry.chemical_compound, Psoriatic arthritis, Prednisone, Internal medicine, medicine, Immunology and Allergy, Humans, Prospective Studies, Triglycerides, medicine.diagnostic_test, Triglyceride, biology, Cholesterol, business.industry, C-reactive protein, Arthritis, Psoriatic, Cholesterol, HDL, Antibodies, Monoclonal, General Medicine, Cholesterol, LDL, Middle Aged, medicine.disease, Lipid Metabolism, Infliximab, Endocrinology, C-Reactive Protein, chemistry, Antirheumatic Agents, biology.protein, Female, business, Lipid profile, lcsh:RC581-607, medicine.drug, Research Article
Abstract

Objectives. To evaluate lipid profile changes after anti-TNF therapy in patients with psoriatic arthritis (PsA).Methods. Fifteen PsA patients (eight polyarticular, four oligoarticular, two axial, and one mutilating) under infliximab were included. None had dyslipoproteinemia or previous statin use. Total cholesterol (TC) and its fractions, inflammatory markers, and prednisone use were evaluated.Results. The comparisons of lipid levels between baseline and after three months (3M) of anti-TNF therapy showed that there was a significant increase in mean triglycerides (117.8±49.7versus140.1±64.1 mg/dL,P=0.028) and VLDL-c (23.6±10.5versus28.4±13.7 mg/dL,P=0.019) levels. In contrast, there were no differences in the mean TC (P=0.28), LDL-c (P=0.42), and HDL-c (P=0.26) levels. Analysis of the frequencies of each lipid alteration at baseline and at 3M were alike (P>0.05). Positive correlations were found between VLDL-c and CRP (r=0.647,P=0.009) and between triglycerides and CRP (r=0.604,P=0.017) levels at 3M. ESR reduction was observed after 3M (P=0.04). Mean prednisone dose remained stable at beginning and at 3M (P=0.37).Conclusion. This study demonstrated that anti-TNF may increase TG and VLDL-c levels in PsA patients after three months.

Published
2011

Catalog

Books, media, physical & digital resources
See catalog results